Identification of Molecular Markers of Clozapine Action in Ketamine-Induced Cognitive Impairment: A GPCR Signaling PathwayFinder Study
Background: Cognitive disorders associated with schizophrenia are closely linked to prefrontal cortex (PFC) dysfunction. Administration of the non-competitive NMDA receptor antagonist ketamine (KET) induces cognitive impairment in animals, producing effects similar to those observed in schizophrenic...
Enregistré dans:
Auteurs principaux: | Agata Korlatowicz, Maciej Kuśmider, Marta Szlachta, Paulina Pabian, Joanna Solich, Marta Dziedzicka-Wasylewska, Agata Faron-Górecka |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bdffb22fddcf4d70b777e83dfe97f5e5 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
A survey of personnel and services offered in 32 outpatient US clozapine clinics
par: Robert O. Cotes, et autres
Publié: (2021) -
Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
par: Fitri Fareez Ramli, et autres
Publié: (2021) -
Effects of somatic treatments on suicidal ideation and completed suicides
par: Elise M Hawkins, et autres
Publié: (2021) -
Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia
par: Amina Aissa, et autres
Publié: (2022) -
Clozapine As Transformative Treatment In Bipolar Patients
par: Wilkowska A, et autres
Publié: (2019)